Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2024 | 1 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma.
Eur J Cancer. 2022 Nov;175:125-135. doi: 10.1016/j.ejca.2022.08.005. Epub 2022 Sep 13.
Eur J Cancer. 2022.
PMID: 36113242
Clinical Trial.
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.
Wei X, Zou Z, Zhang W, Fang M, Zhang X, Luo Z, Chen J, Huang G, Zhang P, Cheng Y, Liu J, Liu J, Zhang J, Wu D, Chen Y, Ma X, Pan H, Jiang R, Liu X, Ren X, Tian H, Jia Z, Guo J, Si L.
Wei X, et al.
Eur J Cancer. 2024 May;202:114008. doi: 10.1016/j.ejca.2024.114008. Epub 2024 Mar 11.
Eur J Cancer. 2024.
PMID: 38479118
Clinical Trial.
Item in Clipboard
Cite
Cite